Kura Oncology, Inc.
KURA
$7.34
$0.050.69%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 69.17% | 38.30% | 41.08% | 59.87% | 13.94% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 63.25% | 40.99% | 41.00% | 48.91% | 33.01% |
| Operating Income | 51.98% | -40.99% | -41.00% | -48.91% | -33.01% |
| Income Before Tax | 59.80% | -40.94% | -36.75% | -45.37% | -29.21% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 55.09% | -40.94% | -36.75% | -45.37% | -29.21% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 55.09% | -40.94% | -36.75% | -45.37% | -29.21% |
| EBIT | 51.98% | -40.99% | -41.00% | -48.91% | -33.01% |
| EBITDA | 52.20% | -41.22% | -41.25% | -49.11% | -33.18% |
| EPS Basic | 60.14% | -25.19% | -10.18% | -18.51% | -13.24% |
| Normalized Basic EPS | 48.42% | -25.19% | -10.15% | -18.50% | -45.23% |
| EPS Diluted | 60.14% | -25.19% | -10.18% | -18.51% | -13.24% |
| Normalized Diluted EPS | 48.42% | -25.19% | -10.15% | -18.50% | -45.23% |
| Average Basic Shares Outstanding | 12.67% | 12.57% | 24.13% | 22.66% | 14.10% |
| Average Diluted Shares Outstanding | 12.67% | 12.57% | 24.13% | 22.66% | 14.10% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
